Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trials in Los Angeles, California
4 recruitingLos Angeles, California
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1Phase 2
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.190 enrolled9 locationsNCT07285694
Recruiting
Phase 1Phase 2
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science99 enrolled1 locationNCT06615752
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674